SCHEMBL5322808

SCHEMBL5322808

CC(CC(N)=O)CC(N)C(=O)O

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 1/20 0.58
SLC1A3 P43003 5/20 0.52
SLC1A2 P43004 5/20 0.52
SLC1A1 P43005 5/20 0.52
GRIK1 P39086 8/20 0.46
GRIK2 Q13002 4/20 0.46
GRIA4 P48058 3/20 0.46
GRIK3 Q13003 3/20 0.46
GRIK5 Q16478 3/20 0.46
GRIA2 P42262 2/20 0.46
GRIA1 P42261 1/20 0.46
ALOX15 P16050 1/20 0.45
BLM P54132 1/20 0.45
PMP22 Q01453 1/20 0.45
KMT2A Q03164 1/20 0.45
GRM1 Q13255 1/20 0.43
GRM2 Q14416 1/20 0.43
BHMT Q93088 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6663362 1.00 SLC7A5 (0.58) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
SCHEMBL6447117 0.84 SLC7A5 (0.60) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Leucine SCHEMBL4775846 0.83 SLC7A5 (0.78) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Leucine SCHEMBL6130796 0.83 SLC7A5 (0.78) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Leucine SCHEMBL4775848 0.83 SLC7A5 (0.78) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
D-Leucine SCHEMBL4958590 0.83 SLC7A5 (0.78) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Leucine SCHEMBL6130794 0.83 SLC7A5 (0.78) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
SCHEMBL21447999 0.83 SLC7A5 (0.58) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
SCHEMBL874270 0.83 SLC7A5 (0.58) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
SCHEMBL877833 0.83 SLC7A5 (0.58) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070258899-A1 Diagnostic and therapeutic agents KARYON-CTT LTD (FI) 2007-11-08 US disclosed
WO-2007113385-A1 DIAGNOSTIC AND THERAPEUTIC AGENTS KARYON-CTT LTD (FI) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070258899-A1 Diagnostic and therapeutic agents YBX1, MLX, TPX2 SLC7A5 3712/4885SLC1A3 4472/4885SLC1A2 4787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.